$25.69
1.15%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US0042251084
Symbol
ACAD

ACADIA Pharmaceuticals Inc. Stock price

$25.69
+1.65 6.86% 1M
+7.53 41.46% 6M
+7.34 40.00% YTD
+9.11 54.95% 1Y
+8.96 53.56% 3Y
-13.53 34.50% 5Y
-12.38 32.52% 10Y
+15.62 155.11% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.30 1.15%
ISIN
US0042251084
Symbol
ACAD
Industry

Key metrics

Basic
Market capitalization
$4.3b
Enterprise Value
$3.6b
Net debt
positive
Cash
$762.0m
Shares outstanding
168.6m
Valuation (TTM | estimate)
P/E
19.3 | 44.6
P/S
4.3 | 4.0
EV/Sales
3.5 | 3.3
EV/FCF
40.4
P/B
5.3
Financial Health
Equity Ratio
61.7%
Return on Equity
30.9%
ROCE
26.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.0b | $1.1b
EBITDA
$250.5m | $89.6m
EBIT
$236.8m | $85.0m
Net Income
$222.2m | $97.1m
Free Cash Flow
$88.3m
Growth (TTM | estimate)
Revenue
14.4% | 14.0%
EBITDA
645.3% | -10.6%
EBIT
969.4% | 0.9%
Net Income
626.0% | -57.1%
Free Cash Flow
9.9%
Margin (TTM | estimate)
Gross
92.0%
EBITDA
24.6% | 8.2%
EBIT
23.2%
Net
21.8% | 8.9%
Free Cash Flow
8.7%
More
EPS
$1.3
FCF per Share
$0.5
Short interest
9.3%
Employees
654
Rev per Employee
$1.5m
Show more

Is ACADIA Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

ACADIA Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

18x Buy
69%
7x Hold
27%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

Buy
69%
Hold
27%
Sell
4%

Financial data from ACADIA Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,019 1,019
14% 14%
100%
- Direct Costs 82 82
11% 11%
8%
937 937
15% 15%
92%
- Selling and Administrative Expenses 523 523
20% 20%
51%
- Research and Development Expense 324 324
10% 10%
32%
250 250
645% 645%
25%
- Depreciation and Amortization 14 14
19% 19%
1%
EBIT (Operating Income) EBIT 237 237
969% 969%
23%
Net Profit 222 222
626% 626%
22%

In millions USD.

Don't miss a Thing! We will send you all news about ACADIA Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACADIA Pharmaceuticals Inc. Stock News

Neutral
Business Wire
8 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat: Monday, September 8, 2025 at 10:45 a.m. Eastern Time in New York, NY H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat: Tuesday, September 9, 2025 at 8:0...
Neutral
Business Wire
9 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia's business development and corporate strategy and serve as a member of the Company's Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executiv...
Neutral
Business Wire
23 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on August 5, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 63,477 shares of common stock and 49,377 restricted stock units (“RSUs”) to twenty-six new employees under Acadia's 2024 Inducemen...
More ACADIA Pharmaceuticals Inc. News

Company Profile

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Head office United States
CEO Catherine Adams
Employees 654
Founded 1993
Website acadia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today